# Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors

> **NCT04324372** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Advanced Refractory Solid Tumors

## Interventions

- **DRUG:** HEC68498

## Key facts

- **NCT ID:** NCT04324372
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-27
- **Primary completion:** 2021-02-26
- **Final completion:** 2021-03-26
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04324372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04324372, "Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04324372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*